Latest news

• AZ’s Farxiga gets heart failure prevention okay from FDA

  attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ.

• AstraZeneca sells Losec rights as part of refocus strategy

  with high unmet medical need,” said Ruud Dobber, executive vice president of BioPharmaceuticals at AZ.

• AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

  Dave Fredrickson retains his position as head of the global oncology business unit, and Ruud Dobber – formerly AZ’s head of North American commercial operations – will take over the running of

• Is AstraZeneca looking for its next CEO?

  L-R: Ruud Dobber and Mene Pangalos. Speculation about potential successors name Mene Pangalos, AZ’s British-born head of the IMED Biotech Unit and business development chief, and Ruud Dobber,

• AZ gets US green light for new Bydureon formulation

  reduction. Ruud Dobber, president, AstraZeneca US, said: “With the approval of Bydureon BCise, we’re now introducing a new formulation in an improved, easy-to-use device.